Beyond Cancer Presents First-In-Human Clinical Data For Ultra-High Concentration Nitric Oxide Therapy In Solid Tumors During The Society For Immunotherapy Of Cancer 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Beyond Cancer, an affiliate of Beyond Air, Inc. (NASDAQ:XAIR), presented first-in-human clinical data for ultra-high concentration nitric oxide (UNO) therapy in solid tumors at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The Phase 1 study showed promising safety profile and clear evidence of immune system activation. Additional Phase 1 data for UNO is expected in 2024.
November 03, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beyond Air's affiliate, Beyond Cancer, has presented promising clinical data for its UNO therapy in solid tumors. This could potentially boost investor confidence in Beyond Air, as it indicates progress in the company's research and development efforts.
The news is directly related to Beyond Air and its affiliate, Beyond Cancer. The promising clinical data indicates progress in the company's research and development efforts, which could potentially boost investor confidence and have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100